期刊文献+

甲状腺乳头状癌术后甲状旁腺功能减退症影响因素的临床分析 被引量:1

Clinical analysis of the factors influencing hypoparathyroidism after papillary thyroid carcinoma surgery
下载PDF
导出
摘要 目的探讨甲状腺乳头状癌(PTC)术后甲状旁腺功能减退症(HPT)的相关因素。方法 回顾性分析200例PTC患者的临床资料,所有患者均行甲状腺全/近全切除和中央区淋巴结清扫治疗。依据术后甲状旁腺功能减退情况分为实验组(甲状旁腺功能减退, 72例)和对照组(甲状旁腺功能正常, 128例)。分析PTC术后HPT的影响因素及永久性和暂时性HPT的影响因素。结果 200例患者经甲状旁腺激素(PTH)血钙水平检测,共72例患者发生HPT,发生率为36.0%,其中5例为永久性HPT,67例为暂时性HPT。两组患者的年龄、手术范围、有无被膜侵犯、有无自体移植、Ⅵ区淋巴结双侧清扫比较差异有统计学意义(P<0.05)。多因素Logistic回归分析显示,手术范围、被膜侵犯、Ⅵ区淋巴结双侧清扫是术后HPT的独立危险因素(P<0.05)。永久性和暂时性HPT患者的Ⅵ区淋巴结清扫与手术范围的比较差异有统计学意义(P<0.05)。结论 HPT是甲状腺手术常见的术后并发症,其中被膜侵犯、手术范围、Ⅵ区淋巴结清扫是PTC术后HPT独立的危险因素。 Objective To discuss the factors influencing hypoparathyroidism(HPT) after papillary thyroid carcinoma(PTC) surgery. Methods The clinical data of 200 patients with PTC were retrospectively analyzed, and all patients were treated with total/near-total thyroidectomy and lymph node dissection in the central region. According to the postoperative hypoparathyroidism, they were divided into experimental group(hypoparathyroidism, 72 cases) and control group(normal parathyroid function, 128 cases) factors influencing postoperative HPT and permanent and temporary HPT after PTC were analyzed. Results By Parathyroid hormone and blood calcium detection, 72 of 200 patients had HPT, the incidence rate was 36.0%, of which 5 cases were permanent HPT and 67 cases were temporary HPT. There were statistically significant differences in age, extent of surgery, presence or absence of capsule invasion, presence or absence of autograft, and bilateral level Ⅵlymph node dissection between the two groups(P<0.05). Multi-factor Logistic regression analysis showed that the extent of surgery, capsule invasion, and bilateral level Ⅵ lymph node dissection were independent risk factors for postoperative HPT(P<0.05). There was a statistically significant difference between permanent and temporary HPT patients in bilateral level Ⅵ lymph node dissection and the extent of surgery(P<0.05). Conclusion HPT is a common postoperative complication of thyroid surgery, among which capsule invasion, surgical methods, and bilateral level Ⅵ lymph node dissection are independent risk factors for HPT after PTC.
作者 麻通通 柴芳 MA Tong-tong;CHAI Fang(Jinzhou Medical University,Jinzhou 121000,China)
出处 《中国现代药物应用》 2023年第1期31-34,共4页 Chinese Journal of Modern Drug Application
关键词 甲状腺乳头状癌 甲状旁腺功能减退症 血钙水平 甲状旁腺激素 影响因素 Papillary thyroid carcinoma Hypoparathyroidism Blood calcium level Parathyroid hormone Influencing factors
  • 相关文献

参考文献4

二级参考文献46

  • 1Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer [J]. Thyroid, 2009,19(11):1167-1214.
  • 2Hovens GC, Stokkel MP, Kievit J, et al. Associations of serum thyrotropin concentrations with recurrence and death in differen- tiated thyroid cancer [J].J Clin Endocrinol Metab,2007,92(7): 2610-2615.
  • 3Paeini F, Schlumherger M, Oralle H, et al. European consensus for the management of patients with differentiated thyroid carci- noma of the follicular epithelium [ J ]. Eur J Endocrinol,2006,154 (6):787-803.
  • 4Cooper DS, Doherty GM, Haugen BR, et al. Revised manage- ment guidelines for patients with thyroid nodules and differenti- ated thyroid cancer[J]. Thyroid,2009,19(11):1167-1214.
  • 5Kabadi UM, Kabadi MM. Serum thyrotropin in primary hypothy- roidism:a reliable and accurate predictor of optimal daily levo- thyroxine dose[J]. Endocr Praet,2001,7(1):16-18.
  • 6Verhaert N, Vander Poorten V, Delaere P, et al. Levothyroxine replacement therapy after thyroid surgery [J]. B-ENT,2006,2 (13):129-133.
  • 7Roos A, Linn-Rasker SP, Van Domburg RT, et al. The starting dose of levothyroxine in primary hypothyroidism treatment: A prospective, randomized,double-blind trial [J ].Arch Interm Med, 2005,165(15):1714-1720.
  • 8Santini F, Pinchera A, Marsili A,et al. Lean body mass is a ma- jor deteminant of levothyroxine dosage in the treatment of thy- roid diseases [ J ]. J Clin Endocrinol Metab,2005,90( 1 ): 124-127.
  • 9Slawik M, Klawitter B, Meiser E,et aLThyroid hormone replace- ment for central hypothyroidism:A randomized controlled trial comparing two doses of thyroxine with a combination of T4 and triiodothyronine [J]. J Clin Endocrinol Metab, 2007, 92(11): 4115-4122.
  • 10Burmeister LA, Goumaz MO, Mariash CN, et al. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer [J]. J Clin Endocrinol Metab, 1992,75(2):344-350.

共引文献60

同被引文献15

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部